Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Brainstorm Cell (BCLI)
Brainstorm Cell (BCLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,562
  • Shares Outstanding, K 48,982
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,280 K
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCLI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings -0.14 on 11/14/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 573.64% ( -6.05%)
  • Historical Volatility 204.02%
  • IV Percentile 97%
  • IV Rank 58.00%
  • IV High 948.08% on 11/08/23
  • IV Low 56.60% on 08/17/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 667
  • Volume Avg (30-Day) 335
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 19,807
  • Open Int (30-Day) 24,193

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.15
  • Number of Estimates 1
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1504 +59.77%
on 11/10/23
0.4500 -46.60%
on 12/05/23
+0.0703 (+41.35%)
since 11/07/23
3-Month
0.1340 +79.33%
on 10/31/23
1.5100 -84.09%
on 09/08/23
-1.2097 (-83.43%)
since 09/07/23
52-Week
0.1340 +79.33%
on 10/31/23
3.4600 -93.05%
on 03/31/23
-1.2897 (-84.29%)
since 12/07/22

Most Recent Stories

More News
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 0.2402 (-19.21%)
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BCLI : 0.2402 (-19.21%)
BCLI LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BCLI : 0.2402 (-19.21%)
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 0.2402 (-19.21%)
BrainStorm Cell Therapeutics Stock Trading Halted Today

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 0.2402 (-19.21%)
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 0.2402 (-19.21%)
BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...

BCLI : 0.2402 (-19.21%)
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative...

BCLI : 0.2402 (-19.21%)
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...

BCLI : 0.2402 (-19.21%)
BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week...

BCLI : 0.2402 (-19.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

See More

Key Turning Points

3rd Resistance Point 0.4082
2nd Resistance Point 0.3591
1st Resistance Point 0.3282
Last Price 0.2402
1st Support Level 0.2482
2nd Support Level 0.1991
3rd Support Level 0.1682

See More

52-Week High 3.4600
Fibonacci 61.8% 2.1895
Fibonacci 50% 1.7970
Fibonacci 38.2% 1.4045
Last Price 0.2402
52-Week Low 0.1340

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar